Vericel Corp. (VCEL)

[hurley cruppers]

Older 2012 article on Ixmyelocel-T, but what is interesting is that it ties it into today's date, in bold below

https://beyondthedish.wordpress.com/page/164/?iframe=true&theme_preview=true%2Ftag%2Fpluripotency%2F

Stem Cell Helps for Patients with Head and Mouth Injuries


Craniofacial tissue regeneration, particularly bone regeneration has advanced remarkably in the past decade. In fact, facial bone re-growth with stem cells has proven less invasive and more effective than traditional bone regeneration treatments.

A partnership between researchers at the University of Michigan School of Dentistry, the Michigan Center for Oral Health Research and the Ann Arbor-based Aastrom Biosciences Inc. generated a clinical trial that involved 24 patients whose injuries required jawbone reconstruction.

In this clinical trial, patients received either experimental tissue repair cells or traditional guided bone regeneration therapy. The experimental cells in this trial are under development by Aastrom Biosciences and are called “ixmyelocel-T.” Ixmyelocel-T is a patient-specific stem cell from a patient’s bone marrow. It is a mixture of several different types of bone marrow-based stem cells.

Principle investigator and assistant professor at the U of M School of Dentistry Darnell Kaigler explained his rationale for his clinical trial: In patients with jawbone deficiencies who also have missing teeth, it is very difficult to replace the missing teeth so that they look and function naturally. This technology and approach could potentially by used to restore areas of bone loss so that missing teeth can be replaced with dental implants.”

This treatment is best suited for individuals with large defects. Such defects, that result from trauma, disease, or birth defects are very complex, since they involve several different tissue types (bone, gum, and skin). This makes them very challenging to treat. Since ixmyelocel-T is made from the patient’s own stem cells, it generates something completely living and compatible with the patient’s immune system rather than something man-made.

To date, the results from this trial have been very promising. Six-twelve weeks after treatment, patients in this clinical trial receive dental implants, and those who were treated with tissue repair cells had greater bone density and faster bone repair than those who received the traditional guide bone regeneration therapy. Additionally, the group who had received the tissue replacement therapy required fewer secondary bone grafting upon receiving their implants.

The cells for this therapy were extracted from bone marrow aspirations from the hip. Aastrom uses a proprietary system to process and grow the bone marrow stem cells, but once they were ready, they were placed into various areas of the mouth and jaw.

The next step in this research is to use more clinical trials with larger number of patients. Unfortunately, these stem cell treatments are probably 5-10 years away from FDA approval and regular use.

William Giannobile, who is the director of the Michigan Center for Oral Health Research and also the chair of the U-of-M Department of Periodontics and Oral Medicine, is one of the co-principal investigators on this project.


?Posted on August 12, 2012?Categories Bone marrow stem cells, Bone treatments, Craniofacial Regeneration?Tags aastrom biosciences inc, guided bone regeneration, health, medicine, science?1 Commenton Stem Cell Helps for Patients with Head and Mouth Injuries